Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Real-World Data and Chronic Lymphocytic Leukemia

Chronic lymphocytic leukemia (CLL) is the most common leukemia among adults in Western countries.

There is increasing recognition in the value of using RWD alongside RCT data to generate a baseline understanding of the efficacy of treatments for CLL in the real world. As this would allow for a better understanding of unmet needs and inform future comparative effectiveness studies.

View overview page
2:20
The effect of ibrutinib dose-reduction on outcomes of patients with CLL/SLL: real-world evidence
Kerry Rogers • 8 Dec 2023
2:38
Ibrutinib treatment for CLL does not increase the incidence of Richter’s transformation
Paul Hampel • 10 Dec 2023
5:45
Treatment effectiveness of venetoclax-based therapy after BTKi exposure in CLL/SLL
Nilanjan Ghosh • 14 Dec 2023
6:05
Real-world data on the effect of ibrutinib flexible dosing treatment strategies on TTNT in CLL/SLL
Nilanjan Ghosh • 14 Dec 2023
1:17
Dose reductions to manage AEs of ibrutinib treatment for CLL
Mazyar Shadman • 10 Dec 2023
1:31
Clinical outcomes are poor for CLL patients treated with venetoclax post-BTKi exposure
Krish Patel • 11 Dec 2023
1:22
Does acalabrutinib increase the risk of hypertension in patients with CLL?
Alessandra Ferrajoli • 11 Dec 2023
2:09
Real-world incidence of ibrutinib-related cardiotoxicity in CLL: insights from the LLS registry
Lee Greenberger • 9 Dec 2023
1:21
Clinical characteristics and outcomes of the double refractory CLL/SLL patient population
Matthew Davids • 9 Dec 2023
3:52
Clinical outcomes of patients with CLL treated with venetoclax-based regimens
Paul Hampel • 7 Oct 2023
2:19
Safety of concomitant delivery of radiotherapy for second primary malignancy in patients with CLL
Paul Hampel • 7 Oct 2023
2:12
Real-world safety and efficacy of first- and second-generation BTK inhibitors in CLL
Raúl Córdoba • 7 Oct 2023
1:43
Incidence and risk of secondary malignancy in patients with CLL
Lydia Scarfò • 8 Jun 2023
2:40
EPIC update: observational study of first-line acalabrutinib treatment for CLL
Nicolas Martinez-Calle • 11 Jun 2023
5:59
InformCLL registry analysis: ibrutinib vs chemoimmunotherapy for the first-line treatment of CLL/SLL
Nilanjan Ghosh • 8 Dec 2022
1:49
An update on the ‘Watch’ registry: clonoSEQ® MRD monitoring in B-cell malignancies
Krish Patel • 12 Dec 2022
The content of VJHemOnc is intended for healthcare professionals